Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics (CVKD) reported insider transactions by its Chief Financial Officer, Matthew K. Szot. He sold 1,800 shares of common stock on October 24, 2025, and 1,800 shares on October 27, 2025, each at $13.99 per share, coded as open‑market sales (S).
The filing states these trades were executed under a Rule 10b5-1 trading plan adopted on May 9, 2025. Following the reported sales, the officer directly beneficially owns 9,933 shares.
Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan. On 10/24/2025, he sold 1,129 shares of common stock at a weighted average price of $14.03, with trades ranging from $13.99 to $14.10. On 10/27/2025, he sold 1,315 shares at a weighted average price of $13.99, with trades ranging from $13.99 to $14.00. The trading arrangement was adopted on May 9, 2025.
Following these transactions, direct beneficial ownership was 197,404 shares after the first sale and 196,089 shares after the second. He also holds 200,000 shares indirectly through The PVBQ Living Trust, for which he serves as trustee with sole voting and disposition power.
Cadrenal Therapeutics (CVKD) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO sold 1,693 shares of common stock at $13.99, and on 10/13/2025, sold 1,800 shares at $14.07, in each case under a Rule 10b5-1 trading arrangement. Following these sales, the CFO directly beneficially owned 13,533 shares.
Cadrenal Therapeutics (CVKD) reported insider transactions by CEO, Chairman and Director Quang Pham, who is also a 10% owner. Under a Rule 10b5-1 trading arrangement, he sold 1,800 shares on 10/09/2025 at a weighted average price of $14.02 and 1,800 shares on 10/13/2025 at a weighted average price of $14.15. Each sale comprised multiple trades within disclosed price ranges.
Following these transactions, Mr. Pham directly beneficially owns 198,533 shares. He also indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, for which he is trustee with sole voting and disposition power.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 reporting a proposed public sale of 1,693 common shares valued at $23,634.28 to be sold through Morgan Stanley Smith Barney LLC on 10/09/2025 on NASDAQ. The shares were originally issued as founders' shares on 05/17/2022 and were acquired from the issuer.
The filing also lists multiple recent 10b5-1 plan sales by the same seller totaling several thousand shares over 08/27/2025–10/06/2025, including a single sale of 10,900 shares on 09/25/2025 for $153,182.06. The filer attests there is no undisclosed material information and identifies the broker and planned sale date.
Cadrenal Therapeutics, Inc. (CVKD) notice shows an insider intends to sell 1,800 common shares, with an aggregate market value of $25,227.76, on 10/09/2025 via Merrill Lynch on NASDAQ. The shares were acquired as founders shares on 01/25/2022. The filing also discloses several recent secondary sales by the same person, totaling 15,200 shares sold across dates from 08/27/2025 to 10/02/2025 with cumulative gross proceeds of $242,044.83. The filer attests they have no undisclosed material adverse information and the form includes a standard attestation about Rule 10b5-1 plan timing if applicable.
Cadrenal Therapeutics (CVKD) Chief Financial Officer Matthew K. Szot reported a sale of common stock under a prearranged trading plan. The Form 4 shows a disposition of 107 shares at $13.99 per share on 10/06/2025, leaving the reporting person with 17,026 shares beneficially owned. The filing indicates the sale was made pursuant to a Rule 10b5-1 arrangement and is signed by the reporting person.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 107 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1517.26. The planned sale is listed for 10/06/2025 and the shares were originally acquired as founders' shares on 05/17/2022.
The filing also lists multiple recent Rule 10b5-1 sales by the same person between 08/27/2025 and 10/01/2025, totaling substantial share volumes (for example 10,900 shares on 09/25/2025). The filer certifies no undisclosed material adverse information and indicates reliance on a trading plan where applicable.
Cadrenal Therapeutics, Inc. (CVKD) director, CEO and chairman Quang Pham reported a planned sale of 500 shares of common stock executed on 10/02/2025 under a Rule 10b5-1 trading arrangement at prices ranging from $14.04 to $14.27, with a weighted average price of $14.13. Following the transaction, Mr. Pham directly owns 202,133 shares and indirectly holds 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Cadrenal Therapeutics (CVKD) Form 144 notifies the SEC of a proposed sale of 500 common shares to be executed on or about 10/02/2025 through Merrill Lynch (Ponte Vedra Beach, FL) on the NASDAQ. The filing identifies Quang X. Pham as the seller and shows those 500 shares were originally acquired as Founders Shares on 01/25/2022. The filing also discloses a series of sales by the same person over the prior three months: 3,836 shares on 08/27/2025, 1,193 on 08/28/2025, 2,581 on 09/24/2025, 6,790 on 09/25/2025, 419 on 09/29/2025, and 881 on 10/01/2025, with gross proceeds listed for each sale. The filer certifies compliance with Rule 144 representations required by the form.